TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC
Status:
Recruiting
Trial end date:
2023-06-15
Target enrollment:
Participant gender:
Summary
This trial is is an open label, multicenter, randomized controlled phase 3 clinical trial.
The purpose is to compare the efficacy and safety of lenvatinib plus TACE with lenvatinib
alone for advanced HCC patients.